<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">APM</journal-id><journal-title-group><journal-title>Advances in Precision Medicine</journal-title></journal-title-group><issn>2424-8592</issn><eissn>2424-9106</eissn><publisher><publisher-name>Bio-Byword Scientific Publishing Pty. Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18063/APM.v10i4.1047</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>Effect of Intensive Intervention Management on Patients with Chronic Obstructive Pulmonary Disease during Discharge Period</title><url>https://artdesignp.com/journal/APM/10/4/10.18063/APM.v10i4.1047</url><author>WangWei,CaoGang</author><pub-date pub-type="publication-year"><year>2025</year></pub-date><volume>10</volume><issue>4</issue><history><date date-type="pub"><published-time>2025-12-20</published-time></date></history><abstract>Objective: To evaluate the efficacy of structured peri-discharge intensive interventions on pulmonary function, exercise capacity, and dyspnea severity in patients with chronic obstructive pulmonary disease (COPD). Methods:&amp;nbsp;A randomized controlled trial was conducted involving 60 COPD patients eligible for discharge from our department between January 2022 and December 2023. Participants were allocated equally to a control group (routine discharge guidance) or an observation group (routine guidance plus intensive intervention). Both cohorts were monitored for 3 months. Assessments included spirometry (FVC, FEV1, FEV1/FVC), modified Medical Research Council (mMRC) dyspnea scores, 6-minute walk distance (6MWD), and 1-year rehospitalization frequency, evaluated at discharge (baseline), 1 month, and 3 months post-enrollment. Results: Repeated-measures ANOVA indicated significant group-by-time interactions for pulmonary function parameters (F = 7.82&amp;ndash;14.35), mMRC scores (F = 8.24), and 6MWD (F = 9.76) (all&amp;nbsp;p &amp;lt; 0.01). The observation group demonstrated superior improvements in FVC (2.08 &amp;plusmn; 0.30 L vs. 2.29 &amp;plusmn; 0.35 L), FEV1&amp;nbsp;(0.79 &amp;plusmn; 0.19 L vs. 0.95 &amp;plusmn; 0.25 L), and FEV1/FVC ratio (37.98 &amp;plusmn; 4.51% vs. 41.48 &amp;plusmn; 5.03%) at 1 and 3 months compared to controls (all&amp;nbsp;p &amp;lt; 0.01), with progressive gains over time (within-group&amp;nbsp;p &amp;lt; 0.01). At 3 months, the observation group also exhibited lower mMRC scores (2.05 &amp;plusmn; 0.31 vs. 2.41 &amp;plusmn; 0.35) and longer 6MWD distances (282.72 &amp;plusmn; 36.25 m vs. 243.21 &amp;plusmn; 31.12 m) (both&amp;nbsp;p &amp;lt; 0.01). Over the 12-month follow-up, the rehospitalization rate was significantly reduced in the observation group (10.00% vs. 30.00%; RR = 0.33,&amp;nbsp;p = 0.039). Conclusion:&amp;nbsp;Peri-discharge intensive intervention for COPD patients significantly enhances pulmonary function, exercise tolerance, and dyspnea management, while reducing rehospitalization risk.</abstract><keywords>Chronic obstructive pulmonary disease (COPD), Peri-discharge period, Respiratory training, Pulmonary rehabilitation, Dyspnea index</keywords></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>[1] Chinese Medical Association Respiratory Disease Branch COPD Group, 2023, Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (2023 Edition). Chinese Journal of Tuberculosis and Respiration, 46(3): 123&amp;ndash;135.
[2] Agusti A, Celli, B, Criner G, et al., 2023, Global Initiative for Chronic Obstructive Lung Disease (GOLD) Executive Summary: GOLD 2023 Report on the Management of COPD. American Journal of Respiratory and Critical Care Medicine, 207(5): 549&amp;ndash;562.
[3] Rabe K, Hurd S, Anzueto A, et al., 2023, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 207(5): 549&amp;ndash;562.
[4] World Health Organization, 2022, Chronic Obstructive Pulmonary Disease (COPD). EB/OL.
[5] GOLD, 2023, Global Initiative for Chronic Obstructive Lung Disease (GOLD). EB/OL.
[6] Tang P, Cao G, 2025, Effect of Comprehensive Intervention Measures of Education Rehabilitation Monitoring on Patients with Chronic Obstructive Pulmonary Disease. Advances in Precision Medicine, 10(3):123&amp;ndash;129.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
